No Data
Shanghai Pharmaceuticals Unit Slapped With 165.8 Million Yuan Penalty for Anti-Monopoly Law Breaches
The Hong Kong stock market is restructuring the value of pharmaceuticals! Hengrui Medicine has received a premium binding from AstraZeneca, and the stock price once rose over 20%.
① Does the offshore strategy mean that "technology platform premium + international certification" is replacing the traditional PE valuation method as the core logic for valuing Innovative Drugs companies? ② With JACOBIO-B narrowing its annual loss by 56.6% through its core product Galidesivir, can it be inferred that China’s Innovative Drugs companies have broken through the industry curse of "burning money on R&D - ongoing losses"?
SH PHARMA (601607.SH): A subsidiary received an administrative penalty decision, imposing a total fine of 0.166 billion yuan.
On March 21, Gelonghui reported that SH PHARMA (601607.SH) announced that its subsidiary Shanghai Xinyi United Pharmaceutical Materials Co., Ltd. (referred to as "Xinyi United") received the "Administrative Penalty Decision" issued by the Shanghai Municipal Market Supervision Administration. According to the relevant provisions of Articles 56 and 59 of the Anti-Monopoly Law, the Shanghai Municipal Market Supervision Administration comprehensively considered factors such as the nature, degree, duration of Xinyi United's illegal activities and the situation of eliminating the consequences of the illegal activities. Meanwhile, given that Xinyi United proactively reported the situation of reaching a monopoly agreement and provided important evidence, the Shanghai Municipal Market Supervision Administration...
Earnings Preview: SH PHARMA to Report Financial Results on March 27
How strong are the Hong Kong pharmaceutical stocks right now? The Innovative Drugs Index has risen over 30% this year, reaching a near 16-month high.
① The Innovative Drugs Index in the Hong Kong stock market has increased by over 30% this year; why can it compete with Technology stocks? ② There has been a "small peak" in the commercialization of individual stocks; how do Institutions perceive the future market direction?
Is the CRO Concept "Return of the King"? WuXi AppTec aggressively attacks, leading stocks celebrate after performance!
Release the signal?!
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing
